A Systematic Review of Nonclinical Studies on the Effect of Curcumin in Chemo-Therapy-Induced Cardiotoxicity Publisher Pubmed



Armandeh M¹ ; Bameri B¹ ; Samadi M² ; Heidari S³ ; Foroumadi R⁴ ; Abdollahi M¹ Show Affiliations
Source: Current Pharmaceutical Design Published:2022

Abstract

Background: Various anticancer drugs are effective therapeutic agents for cancer treatment; however, they cause severe toxicity in body organs. Cardiotoxicity is one of the most critical side effects of these drugs. Based on various findings, turmeric extract has positive effects on cardiac cells. Objective: This study aims to evaluate how curcumin, as the main component of turmeric, may affect chemo-therapy-induced cardiotoxicity. Methods: A database search was performed up to April 2021 using “curcumin OR turmeric OR Curcuma longa” and “chemotherapy-induced cardiac disease”, including their equivalents and similar terms. After screening the to-tal articles obtained from the electronic databases, 25 relevant articles were included in this systematic review. Results: The studies demonstrate lower body weight and increased mortality rates due to doxorubicin administration. Besides, cancer therapeutic agents induced various morphological and biochemical abnormalities compared to the non-treated groups. Based on most of the obtained results, curcumin at nontoxic doses can protect the cardiac cells mainly through modulating antioxidant capacity, regulation of cell death, and anti-inflammatory effects. Nevertheless, according to a minority of findings, curcumin increases the susceptibility of the rat cardiomyoblast cell line (H9C2) to apoptosis triggered by doxorubicin. Conclusion: According to most nonclinical studies, curcumin could potentially have cardioprotective effects against chemotherapy-induced cardiotoxicity. However, based on limited, contradictory findings demonstrating the function of curcumin in potentiating doxorubicin-induced cardiotoxicity, well-designed studies are needed to evaluate the safety and effectiveness of treatment with new formulations of this compound during cancer therapy. © 2022 Bentham Science Publishers.